- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.10. | Immunovia AB: Immunovia publishes information document regarding rights issue | 336 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 01.10. | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.10.2025 | 422 | Xetra Newsboard | Das Instrument RIHN CH0003671440 RIETER HLDG NA SF 5 EQUITY wird cum Kapitalmassnahme gehandelt am 01.10.2025 und ex Kapitalmassnahme am 02.10.2025 The instrument RIHN CH0003671440 RIETER HLDG NA SF... ► Artikel lesen | |
| 29.09. | Immunovia AB: Bulletin from the extraordinary general meeting in Immunovia AB (publ) | 217 | GlobeNewswire (Europe) | Today, on 29 September 2025, an extraordinary general meeting was held in Immunovia AB (publ). A summary of the adopted resolutions follows below.
Resolution on amendment of the Articles of AssociationThe... ► Artikel lesen | |
| 23.09. | Proteomedix vereinbart Lizenzabkommen mit Immunovia | 1 | punkt4.info | ||
| 22.09. | Onconetix-Tochter lizenziert Biomarker-Technologie an Immunovia | 1 | Investing.com Deutsch | ||
| 22.09. | Onconetix, Inc.: Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM | 453 | GlobeNewswire (Europe) | CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization... ► Artikel lesen | |
| 22.09. | Immunovia AB: Immunovia Secures Control of PancreaSure Supply Chain and Achieves Cost Reduction through Licensing Agreement | 153 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia AB (publ.), the pancreatic cancer diagnostics company, has announced the successful conclusion of an agreement to acquire assets and license intellectual property that will... ► Artikel lesen | |
| 15.09. | Immunovia AB: Inova Schar Cancer Adopts Immunovia's PancreaSure Test for its High-Risk Surveillance Program | 165 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its PancreaSure test will be offered to patients in Inova Schar Cancer's high-risk surveillance program... ► Artikel lesen | |
| 08.09. | Immunovia AB: Immunovia enters into top guarantee commitments for the upcoming rights issue | 192 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 28.08. | Immunovia Q2 2025 slides: PancreaSure launch plan unveiled amid stock decline | 3 | Investing.com | ||
| 28.08. | Immunovia-Aktie bricht nach Q2-Zahlen ein - trotz neuem Krebstest | 3 | Investing.com Deutsch | ||
| 28.08. | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 133 | GlobeNewswire (Europe) | April-June 2025Net sales, which for the quarter only included royalties, amounted to 90 KSEK (85).Operating loss was -20.1 MSEK, down from -23.9 MSEK in the second quarter of 2024. Net earnings were... ► Artikel lesen | |
| 27.08. | Immunovia AB: Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans | 390 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 19.08. | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 147 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen | |
| 14.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2025 | 242 | GlobeNewswire (Europe) | January-March 2025• Net sales, which for the quarter only included royalties, amounted to 139 KSEK (156).• Net earnings were -57.8 MSEK (-2.9), as a result of unrealized exchange rate effects due to... ► Artikel lesen | |
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 245 | PR Newswire | LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results... ► Artikel lesen | |
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 222 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic... ► Artikel lesen | |
| 19.03. | Immunovia AB: Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test | 207 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation... ► Artikel lesen | |
| 25.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2024 | 275 | PR Newswire | LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October- December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
... ► Artikel lesen | |
| 31.01. | Change in number of shares and votes in Immunovia AB (publ) | 336 | PR Newswire | LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 32,870 | +0,15 % | Hims, Block, and NRG Just Launched Huge Stock Buybacks | ||
| BECTON DICKINSON | 164,55 | -0,72 % | BD Launches Surgiphor Surgical Wound Irrigation System In Europe | WASHINGTON (dpa-AFX) - Becton, Dickinson and Company (BDX), a medical technology company, said Monday that it has launched the BD Surgiphor Surgical Wound Irrigation System in Europe. The system... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,350 | +0,97 % | RYMAN HEALTHCARE LIMITED: Successful completion of full bank debt refinance | ||
| SOLENO THERAPEUTICS | 38,840 | +2,16 % | BREAKING: Soleno Therapeutics nach Short-Report massiv unter Beschuss | "Der größte reine Biotech-Betrug in den USA gemessen an der Marktkapitalisierung", hat Scorpion Capital vor Kurzem auf der Kurznachrichtenplattform X geschrieben. Der aktivistische Leerverkäufer knöpft... ► Artikel lesen | |
| SIENNA SENIOR LIVING | 12,600 | 0,00 % | Sienna Senior Living: Sienna Reports Third Quarter 2025 Financial Results and Continues Growth in Greater Toronto Area | MARKHAM, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced its financial results for the three and nine months ended September... ► Artikel lesen | |
| NIAGEN BIOSCIENCE | 5,800 | -2,52 % | Niagen Bioscience, Inc: Niagen Bioscience to Participate at the Roth 15th Annual London Conference | Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces... ► Artikel lesen | |
| MICROPORT SCIENTIFIC | 1,200 | +2,56 % | BofAS Slightly Lifts MICROPORT TP to $17, Reaffirms Buy Rating | ||
| EXTENDICARE | 12,300 | 0,00 % | XFRA 5XE: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEXTENDICARE INC.... ► Artikel lesen | |
| VERADIGM | 3,600 | 0,00 % | Veradigm Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| NATIONAL HEALTHCARE CORPORATION | 112,00 | 0,00 % | Dividendenbekanntmachungen (30.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1705 EUR ADVANCED FLOWER CAPITAL INC US00109K1051 0,15 USD 0,1279 EUR AG MORTGAGE INVESTMENT... ► Artikel lesen | |
| HANGZHOU TIGERMED CONSULTING | 4,340 | 0,00 % | Tigermed Selected as "2025 Forbes China Go-International Flagship Brands" Top 30 | HANGZHOU, China, Nov. 6, 2025 /PRNewswire/ -- Tigermed has been selected as one of the Top 30 companies on the "2025 Forbes China Go-International Flagship Brands" list, Forbes China... ► Artikel lesen | |
| UNIPHAR | 3,505 | -0,28 % | Dividendenbekanntmachungen (11.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADEMY SPORTS AND OUTDOORS INC US00402L1070 0,13 USD 0,1111 EUR ACTIA GROUP SA FR0000076655 - 0,12 EUR ADT INC US00090Q1031 0... ► Artikel lesen | |
| AESTHETIC MEDICAL INTERNATIONAL | 0,108 | 0,00 % | Aesthetic Medical International Holdings Group Ltd - 6-K, Report of foreign issuer | ||
| HEARTFLOW | 30,850 | 0,00 % | Heartflow, Inc.: Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform | MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received... ► Artikel lesen |
IMMUNOVIA AB gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +8,33 % bei einem Aktienkurs von 0,004 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.